<p>隨着全球市場在複雜的環境中航行，亞洲股票仍然是尋求超越傳統界限機會的投資者的焦點。儘管 “便士股票” 這一稱謂有些過時，但由於其增長潛力和可負擔性，仍然吸引着投資者的關注。本文探討了三隻展現財務實力和長期價值潛力的亞洲便士股票。</p>
<h3>亞洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.47</td>
<td>HK$909.23M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)</td>
<td>THB2.62</td>
<td>THB1.1B</td>
<td>✅ 3 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.53</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Atlantic Navigation Holdings (Singapore) (Catalist:5UL)</td>
<td>SGD0.102</td>
<td>SGD53.4M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.47</td>
<td>SGD13.66B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Anton Oilfield Services Group (SEHK:3337)</td>
<td>HK$0.77</td>
<td>HK$2.04B</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>NagaCorp (SEHK:3918)</td>
<td>HK$4.82</td>
<td>HK$21.32B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$1.00</td>
<td>NZ$137.01M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.32</td>
<td>HK$50.15B</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Scott Technology (NZSE:SCT)</td>
<td>NZ$2.89</td>
<td>NZ$243.04M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲便士股票篩選器的 952 只股票的完整列表。</p>
<p>我們將查看篩選工具中一些最佳選擇。</p>
<h2>上海復旦張江生物醫藥有限公司 (SEHK:1349)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 上海復旦張江生物醫藥有限公司專注於中國生物醫藥產品的研究、開發、生產和銷售，市值為 HK$78.7 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自其製藥部門，最近報告的收入為 CN¥7.1163 億。</p>
<p><strong>市值：</strong> HK$78.7B</p>
<p>上海復旦張江生物醫藥有限公司市值為 HK$78.7 億，主要從製藥部門產生收入，最近報告的收入為 CN¥7.1163 億。儘管沒有債務，但公司目前處於虧損狀態，過去五年虧損以顯著的年率增加。最近的發展包括獲得中國 NMPA 對 FZ-P001 注射用鈉在肺癌患者中進行二期臨牀試驗申請的接受，可能增強其產品管線。董事會經歷了變動，監督委員會解散，監督職責轉移至審計委員會。</p>
<ul>
<li>點擊這裏發現上海復旦張江生物醫藥有限公司的細微差別，查看我們的詳細分析財務健康報告。</li>
<li>探索歷史數據，以跟蹤上海復旦張江生物醫藥有限公司的表現，查看我們的過去業績報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/17108f6f-08d2-4b56-af64-ef5de95fe2fe/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/17108f6f-08d2-4b56-af64-ef5de95fe2fe/chart/financial-position-analysis"/></p>
<p>SEHK:1349 財務狀況分析截至 2026 年 1 月</p>
<h2>博雅互動國際 (SEHK:434)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 博雅互動國際有限公司是一家投資控股公司，在中華人民共和國和香港開發和運營在線紙牌和棋盤遊戲，市值為 HK$27.8 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自其移動遊戲相關業務，產生 HK$4.3855 億，此外還有 HK$6.178 百萬來自其 Web3 相關業務。</p>
<p><strong>市值：</strong> HK$27.8B</p>
<p>博雅互動國際市值為 HK$27.8 億，展現出強勁的財務健康狀況，因為其無債務運營，並且短期資產 HK$39 億超過其負債。公司經歷了顯著的收益增長，過去一年增長了 353%，超過行業平均水平。儘管最近的指導表明，由於銀行存款減少和税費增加，核心利潤可能會下降，但博雅的股本回報率仍保持在 33.8% 的強勁水平。以 2.3 倍的低市盈率交易，相較於市場平均水平，表明投資者在亞洲遊戲行業的便士股票中可能存在價值。</p>
<ul>
<li>點擊這裏瞭解博雅互動國際的複雜財務狀況，查看我們的綜合資產負債表健康報告。</li>
<li>通過查看我們的增長報告，瞭解博雅互動國際的收益前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bdec9b56-66a0-4431-8cb6-9ffe7e6228b2/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bdec9b56-66a0-4431-8cb6-9ffe7e6228b2/chart/debt-equity-history-analysis"/></p>
<p>SEHK:434 債務與股本歷史及分析截至 2026 年 1 月</p>
<h2>中築醫療控股有限公司 (SHSE:600568)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 中築醫療控股有限公司專注於中國藥物的研究、開發、生產和銷售，市值為 CN¥48.7 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自其在中國的運營，總計 CN¥5.7062 億。</p>
<p><strong>市值：</strong> CN¥48.7B</p>
<p>中柱醫療控股有限公司市值為 48.7 億人民幣，運營無負債，短期資產強勁，達到 12 億人民幣，足以覆蓋其負債。儘管公司未盈利，股本回報率為-32.97%，但在截至 2025 年 9 月的九個月內，淨虧損已從 9242 萬人民幣減少至 3379 萬人民幣。收入從去年同期的 3.839 億人民幣增加至 4.3313 億人民幣，反映出在管理團隊經驗不足和董事會平均任期僅 1.1 年的挑戰中，仍有一些積極的勢頭。</p>
<ul>
<li>在這裏深入瞭解中柱醫療控股有限公司的具體情況，查看我們的全面資產負債表健康報告。</li>
<li>查看我們的歷史業績報告，以獲取中柱醫療控股有限公司的業績記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis"/></p>
<p>SHSE:600568 財務狀況分析截至 2026 年 1 月</p>
<h2>總結</h2>
<ul>
<li>在這裏發現 952 只亞洲便士股票的完整陣容。</li>
<li>想要探索一些替代方案？通過提供可靠收入來源的穩健分紅股票來多樣化您的投資組合，以應對潛在的市場波動。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容為一般性信息。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

博雅互動

復旦張江

<p>這篇文章強調了三隻亞洲便士股票，包括上海復旦張江生物醫藥有限公司、博雅互動國際和中珠醫療控股有限公司，這些股票顯示出增長潛力。上海復旦張江專注於生物醫藥，市值為 78.7 億港元，但目前尚未盈利。博雅互動的估值為 27.8 億港元，儘管潛在利潤可能下降，但其收益增長顯著。中珠醫療的市值為 48.7 億人民幣，雖然也未盈利，但其淨虧損同比有所減少。在複雜的市場環境中，這些股票正吸引投資者的關注</p>

<p>As global markets navigate a complex landscape, Asian stocks remain a focal point for investors seeking opportunities beyond traditional boundaries. Penny stocks, despite their somewhat outdated moniker, continue to capture interest due to their potential for growth and affordability. This article explores three Asian penny stocks that exhibit financial strength and the potential for long-term value.</p>
<div class="lb-trans"><p>隨着全球市場在複雜的環境中航行，亞洲股票仍然是尋求超越傳統界限機會的投資者的焦點。儘管 “便士股票” 這一稱謂有些過時，但由於其增長潛力和可負擔性，仍然吸引着投資者的關注。本文探討了三隻展現財務實力和長期價值潛力的亞洲便士股票。</p>
</div><h3>Top 10 Penny Stocks In Asia</h3>
<div class="lb-trans"><h3>亞洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.47</td>
<td>HK$909.23M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)</td>
<td>THB2.62</td>
<td>THB1.1B</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.53</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Atlantic Navigation Holdings (Singapore) (Catalist:5UL)</td>
<td>SGD0.102</td>
<td>SGD53.4M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.47</td>
<td>SGD13.66B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Anton Oilfield Services Group (SEHK:3337)</td>
<td>HK$0.77</td>
<td>HK$2.04B</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>NagaCorp (SEHK:3918)</td>
<td>HK$4.82</td>
<td>HK$21.32B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$1.00</td>
<td>NZ$137.01M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.32</td>
<td>HK$50.15B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Scott Technology (NZSE:SCT)</td>
<td>NZ$2.89</td>
<td>NZ$243.04M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.47</td>
<td>HK$909.23M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)</td>
<td>THB2.62</td>
<td>THB1.1B</td>
<td>✅ 3 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.53</td>
<td>HK$2.1B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Atlantic Navigation Holdings (Singapore) (Catalist:5UL)</td>
<td>SGD0.102</td>
<td>SGD53.4M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.47</td>
<td>SGD13.66B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Anton Oilfield Services Group (SEHK:3337)</td>
<td>HK$0.77</td>
<td>HK$2.04B</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>NagaCorp (SEHK:3918)</td>
<td>HK$4.82</td>
<td>HK$21.32B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$1.00</td>
<td>NZ$137.01M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.32</td>
<td>HK$50.15B</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Scott Technology (NZSE:SCT)</td>
<td>NZ$2.89</td>
<td>NZ$243.04M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 952 stocks from our Asian Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲便士股票篩選器的 952 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看篩選工具中一些最佳選擇。</p>
</div><h2>Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (SEHK:1349)</h2>
<div class="lb-trans"><h2>上海復旦張江生物醫藥有限公司 (SEHK:1349)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. focuses on the research, development, manufacture, and sale of bio-pharmaceutical products in China with a market cap of HK$7.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 上海復旦張江生物醫藥有限公司專注於中國生物醫藥產品的研究、開發、生產和銷售，市值為 HK$78.7 億。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its pharmaceuticals segment, which generated CN¥711.63 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其製藥部門，最近報告的收入為 CN¥7.1163 億。</p>
</div><p><strong>Market Cap:</strong> HK$7.87B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$78.7B</p>
</div><p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has a market cap of HK$7.87 billion and primarily generates revenue from its pharmaceuticals segment, with CN¥711.63 million reported recently. Despite being debt-free, the company is currently unprofitable, with losses increasing over the past five years by a significant rate annually. Recent developments include receiving acceptance from China's NMPA for a Phase II clinical trial application of FZ-P001 Sodium for Injection in lung cancer patients, potentially enhancing its product pipeline. The board underwent changes with the dissolution of its Supervisory Committee, transferring oversight responsibilities to the audit committee.</p>
<div class="lb-trans"><p>上海復旦張江生物醫藥有限公司市值為 HK$78.7 億，主要從製藥部門產生收入，最近報告的收入為 CN¥7.1163 億。儘管沒有債務，但公司目前處於虧損狀態，過去五年虧損以顯著的年率增加。最近的發展包括獲得中國 NMPA 對 FZ-P001 注射用鈉在肺癌患者中進行二期臨牀試驗申請的接受，可能增強其產品管線。董事會經歷了變動，監督委員會解散，監督職責轉移至審計委員會。</p>
</div><ul>
<li>Click here to discover the nuances of Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd with our detailed analytical financial health report.</li>
<li>Explore historical data to track Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現上海復旦張江生物醫藥有限公司的細微差別，查看我們的詳細分析財務健康報告。</li>
<li>探索歷史數據，以跟蹤上海復旦張江生物醫藥有限公司的表現，查看我們的過去業績報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/17108f6f-08d2-4b56-af64-ef5de95fe2fe/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/17108f6f-08d2-4b56-af64-ef5de95fe2fe/chart/financial-position-analysis"/></p>
<p>SEHK:1349 Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:1349 財務狀況分析截至 2026 年 1 月</p>
</div><h2>Boyaa Interactive International (SEHK:434)</h2>
<div class="lb-trans"><h2>博雅互動國際 (SEHK:434)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Boyaa Interactive International Limited is an investment holding company that develops and operates online card and board games in the People’s Republic of China and Hong Kong, with a market cap of HK$2.78 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 博雅互動國際有限公司是一家投資控股公司，在中華人民共和國和香港開發和運營在線紙牌和棋盤遊戲，市值為 HK$27.8 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Mobile Game Related Business, generating HK$438.55 million, complemented by HK$61.78 million from its Web3 Related Business.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其移動遊戲相關業務，產生 HK$4.3855 億，此外還有 HK$6.178 百萬來自其 Web3 相關業務。</p>
</div><p><strong>Market Cap:</strong> HK$2.78B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$27.8B</p>
</div><p>Boyaa Interactive International, with a market cap of HK$2.78 billion, shows strong financial health as it operates without debt and maintains high liquidity with short-term assets of HK$3.9 billion exceeding its liabilities. The company has experienced significant earnings growth, notably 353% over the past year, surpassing industry averages. Despite recent guidance indicating a potential decrease in core profit due to reduced bank deposits and increased tax expenses, Boyaa's Return on Equity remains robust at 33.8%. Trading at a low P/E ratio of 2.3x compared to the market average suggests potential value for investors seeking opportunities in penny stocks within Asia's gaming sector.</p>
<div class="lb-trans"><p>博雅互動國際市值為 HK$27.8 億，展現出強勁的財務健康狀況，因為其無債務運營，並且短期資產 HK$39 億超過其負債。公司經歷了顯著的收益增長，過去一年增長了 353%，超過行業平均水平。儘管最近的指導表明，由於銀行存款減少和税費增加，核心利潤可能會下降，但博雅的股本回報率仍保持在 33.8% 的強勁水平。以 2.3 倍的低市盈率交易，相較於市場平均水平，表明投資者在亞洲遊戲行業的便士股票中可能存在價值。</p>
</div><ul>
<li>Navigate through the intricacies of Boyaa Interactive International with our comprehensive balance sheet health report here.</li>
<li>Understand Boyaa Interactive International's earnings outlook by examining our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解博雅互動國際的複雜財務狀況，查看我們的綜合資產負債表健康報告。</li>
<li>通過查看我們的增長報告，瞭解博雅互動國際的收益前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/bdec9b56-66a0-4431-8cb6-9ffe7e6228b2/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/bdec9b56-66a0-4431-8cb6-9ffe7e6228b2/chart/debt-equity-history-analysis"/></p>
<p>SEHK:434 Debt to Equity History and Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:434 債務與股本歷史及分析截至 2026 年 1 月</p>
</div><h2>Zhongzhu Healthcare HoldingLtd (SHSE:600568)</h2>
<div class="lb-trans"><h2>中築醫療控股有限公司 (SHSE:600568)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Zhongzhu Healthcare Holding Co., Ltd focuses on the research, development, production, and sale of drugs in China with a market cap of CN¥4.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中築醫療控股有限公司專注於中國藥物的研究、開發、生產和銷售，市值為 CN¥48.7 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from its operations in China, totaling CN¥570.62 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其在中國的運營，總計 CN¥5.7062 億。</p>
</div><p><strong>Market Cap:</strong> CN¥4.87B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥48.7B</p>
</div><p>Zhongzhu Healthcare Holding Co., Ltd, with a market cap of CN¥4.87 billion, operates without debt and has robust short-term assets of CN¥1.2 billion, comfortably covering its liabilities. Despite being unprofitable with a negative Return on Equity of -32.97%, the company has managed to reduce its net loss from CN¥92.42 million to CN¥33.79 million year-over-year for the nine months ending September 2025. Revenue increased to CN¥433.13 million from CN¥383.9 million in the previous year, reflecting some positive momentum amidst challenges such as an inexperienced management team and board of directors with an average tenure of 1.1 years each.</p>
<div class="lb-trans"><p>中柱醫療控股有限公司市值為 48.7 億人民幣，運營無負債，短期資產強勁，達到 12 億人民幣，足以覆蓋其負債。儘管公司未盈利，股本回報率為-32.97%，但在截至 2025 年 9 月的九個月內，淨虧損已從 9242 萬人民幣減少至 3379 萬人民幣。收入從去年同期的 3.839 億人民幣增加至 4.3313 億人民幣，反映出在管理團隊經驗不足和董事會平均任期僅 1.1 年的挑戰中，仍有一些積極的勢頭。</p>
</div><ul>
<li>Dive into the specifics of Zhongzhu Healthcare HoldingLtd here with our thorough balance sheet health report.</li>
<li>Review our historical performance report to gain insights into Zhongzhu Healthcare HoldingLtd's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解中柱醫療控股有限公司的具體情況，查看我們的全面資產負債表健康報告。</li>
<li>查看我們的歷史業績報告，以獲取中柱醫療控股有限公司的業績記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis"/></p>
<p>SHSE:600568 Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:600568 財務狀況分析截至 2026 年 1 月</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Discover the full array of 952 Asian Penny Stocks right here.</li>
<li>Want To Explore Some Alternatives? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏發現 952 只亞洲便士股票的完整陣容。</li>
<li>想要探索一些替代方案？通過提供可靠收入來源的穩健分紅股票來多樣化您的投資組合，以應對潛在的市場波動。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容為一般性信息。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

上海復旦張江生物醫藥有限公司及其他兩隻亞洲低價股值得密切關注